Stellar Biotechnologies (NASDAQ:SBOT) issued its quarterly earnings data on Tuesday, February 5th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03), Bloomberg Earnings reports. The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.06 million. Stellar Biotechnologies had a negative return on equity of 52.71% and a negative net margin of 2,018.40%.
Shares of NASDAQ:SBOT remained flat at $$1.13 during midday trading on Wednesday. The stock had a trading volume of 54,765 shares, compared to its average volume of 271,793. Stellar Biotechnologies has a twelve month low of $0.75 and a twelve month high of $7.63. The stock has a market capitalization of $5.86 million, a P/E ratio of -0.64 and a beta of 1.11.
Separately, ValuEngine raised Stellar Biotechnologies from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.
About Stellar Biotechnologies
Stellar Biotechnologies, Inc, a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market.
Read More: Swap
Receive News & Ratings for Stellar Biotechnologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Stellar Biotechnologies and related companies with MarketBeat.com’s FREE daily email newsletter.